Léauté⁃Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propanolol for severe hemangiomas of infancy[J]. N EngI J Med, 2008, 358(24): 2649⁃2651. DOI: 10.1056/NEJMc0708819.
[2]
Zheng M, Zhu W. Han Q, et a1. Emerging concepts and therapeutic implications of beta⁃adrenergic receptor subtype signaling[J].Pharmacol Ther, 2005, 108(3): 257⁃268. DOI: 10.1016/j.pharmthera.2005.04.006.
[3]
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas[J]. Pediatrics, 2011, 128(2): e259⁃e266. DOI: 10.1542/peds.2010⁃0029.
Zhu Y, Tuerxun A, Hui Y, et al. Effects of propranolol and isoproterenol on infantile hemangioma endothelial cells in vitro[J]. Exp Ther Med, 2014, 8(2): 647⁃651.
[6]
Denoyelle F, Leboulanger N, Eajolras O, et al. Role of propranolol in the therapeutic strategy of infantile laryngotrachealhaemangioma[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(8): 1168⁃1172. DOI: 10.1016/j.ijporl.2009.04.025.
[7]
Schuller HM. Neurotransmitter receptor⁃mediated signaling path⁃ways as modulators of carcinogenesis[J]. Prog Exp Tumor Res, 2007, 39: 45⁃63. DOI: 10.1159/0000100045.